CRMD (cormedix.com) רווח נקי למניה (EPS TTM)

The annual net income per share trend demonstrates profit dynamics, where 0.66 records a new level. Growth is driven by a lack of direct competitors and strong pricing power. The integration of Defencath into US medical standards and patent protection are creating positive momentum. CorMedix Inc. is strengthening its status as a reliable lifesaver by developing highly effective anti-infective solutions for dialysis.
CorMedix Corp (CRMD) - פילוחי מדדים ודוחות פיננסיים

To select high-quality assets, an investor must compare a business's real returns with its market value using fundamental metrics. Earnings per share (TTM) measures the final financial result over a rolling year distributed across the total share issuance, which allows for an assessment of CorMedix Inc. antimicrobial solution sales efficiency through changes in rolling earnings per share.